Clay Siegall’s Success With Seattle Genetics

Clay B. Siegall’s interest in cancer and cancer therapies started when the entrepreneur was only 19 years. His interest was sparked when his father was diagnosed with cancer. In the following five years, Clay supported his father as he put a spirited fight against cancer. Later, his father died. This experience helped Dr. Siegall to learn the shortcomings of treating cancer, thus cementing his resolve to correct this shortfall. He joined medical school where he pursued his undergraduate degree. Clay enrolled in George Washington University where he completed his doctorate degree in genetics. After graduating, he started working as a researcher at the Bristol-Myers Squibb.

In his interview with Ideamensch, Dr. Siegall advised individuals in their 20s to read widely and associate with experts in their fields if they are seeking to be experts in their respective areas of specialization. He notes that at such a young age, one has limited knowledge that continues to expand as one grows. Siegall uses an example of himself as a 40-year-old. Today, he is more knowledgeable and wiser than he was in his 20s. This information was originally mentioned on Ideamensch as provided in this link

Dr. Siegall said that he was thankful for his collaboration strategy, which enhanced the company’s operations. Seattle Genetics has continuously collaborated with other industry leaders and innovators to advance the ADCs technology. This way, the corporation has been able to develop and release advanced cancer therapies, such as the Adcetris, into the market.

About Clay Siegall

Clay Siegall is the co-founder and the president of Seattle Genetics. The genetics expert has over 30 years of experience in cancer research. His knowledge in the industry is unrivaled. Siegall founded Seattle Genetics in 1998. Through his transformative leadership, the company has been able to operate as a going concern. The corporation has been working with several research and pharmaceutical companies such as Genentech, GlaxoSmithKline, AbbVie, and Pfizer. Dr. Siegall has been the key figure behind different partnerships that have helped the biotech company generate more than $35 million through strategic licenses. The scientist has also helped the company to raise over $1.2 billion in public and private funding. Clay was the recipient of the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences.